109 related articles for article (PubMed ID: 2557698)
21. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
22. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
Horvath LG; McCaughan BC; Stockle M; Boyer MJ
Intern Med J; 2002 Mar; 32(3):79-83. PubMed ID: 11885847
[TBL] [Abstract][Full Text] [Related]
23. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
24. [Retroperitoneal lymph node dissection for patients with advanced testicular tumor].
Takasaki N; Ueda H; Isurugi K
Hinyokika Kiyo; 1994 Oct; 40(10):957-61. PubMed ID: 7992714
[TBL] [Abstract][Full Text] [Related]
25. Postchemotherapy surgery in nonseminomatous testicular tumors.
Hornák M; Ondrus D; Matoska J; Cársky S
Eur Urol; 1996; 29(3):325-30. PubMed ID: 8740018
[TBL] [Abstract][Full Text] [Related]
26. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
27. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
28. Current concepts in risk factor assessment for advanced germ cell cancer.
Garzotto M; Nichols CR
Semin Urol Oncol; 2001 Aug; 19(3):165-9. PubMed ID: 11561983
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer.
Matsuyama H; Yamamoto N; Sakatoku J; Suga A; Hayashida S; Kamiryo Y; Nagata K; Naito K
Urology; 1994 Sep; 44(3):392-8; discussion 398-9. PubMed ID: 8073552
[TBL] [Abstract][Full Text] [Related]
30. [Clinical study of retroperitoneal lymph node dissection for patients with advanced germ cell tumors].
Okamura K; Yuba H; Nishimura T; Mizutani K; Takashi M; Gotoh M; Ono Y; Ohshima S
Hinyokika Kiyo; 1999 Feb; 45(2):95-101. PubMed ID: 10212781
[TBL] [Abstract][Full Text] [Related]
31. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer.
Andreopoulou E; Andreopoulos D; Adamidis K; Fountzila-Kalogera A; Fountzilas G; Dimopoulos MA; Aravantinos G; Zamboglou N; Baltas D; Pavlidis N
Anticancer Res; 2002; 22(3):1903-8. PubMed ID: 12168891
[TBL] [Abstract][Full Text] [Related]
32. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
Steiner H; Peschel R; Bartsch G
BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
[TBL] [Abstract][Full Text] [Related]
33. [Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].
Otto T; Goepel M; Seeber S; Rübben H
Urologe A; 1993 May; 32(3):189-93. PubMed ID: 7685554
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapeutic treatment regimens for germinal testicular tumors].
Hofmann W; Langkopf B; Heinrichs HJ; Rebmann U
Z Urol Nephrol; 1983 Nov; 76(11):741-50. PubMed ID: 6320553
[No Abstract] [Full Text] [Related]
35. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
[TBL] [Abstract][Full Text] [Related]
36. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
37. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
38. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
39. Is the blood-brain barrier relevant in metastatic germ cell tumor?
Azar JM; Schneider BP; Einhorn LH
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):163-6. PubMed ID: 17707269
[TBL] [Abstract][Full Text] [Related]
40. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
